SLC1A5 and colorectal carcinoma: These data indicate that upregulation of these three AATs (SLC1A5/ASCT2, SLC7A5/LAT1, and SLC38A2/SNAT2) likely contribute to enhanced cellular accumulation of glutamine and leucine in KRAS mutant CRC cells, followed by mTOR activation.